- Language: English
- 56 Pages
- Published: October 2013
- Region: Global
Global Hemophilia Market 2014-2018
- Published: November 2013
- Region: Global
- 61 Pages
The analysts forecast the Global Hemophilia market to grow at a CAGR of 6.07 percent over the period 2013-2018. One of the key factors contributing to this market growth is the development of new hemophilia therapeutics. The Global Hemophilia market has also been witnessing the increase in technological innovations. However, the high cost of hemophilia therapeutics could pose a challenge to the growth of this market.
The report, the Global Hemophilia Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hemophilia market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Baxter International Inc., Bayer AG., Novo Nordisk A/s-b., and Pfizer Inc.
Other vendors mentioned in the report are Biogen Idec, Inc., CSL Behring LLC., Grifols S.A, Inspiration Biopharmaceuticals Inc., Kedrion Biopharma Inc., Octapharma AG., and Swedish Orphan Biovitrum AB.
Key questions answered in this report:
- What will the market size be in 2016/2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report. SHOW LESS READ MORE >
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
07. Hemophilia Product Pipeline
07.1 Five Forces Analysis
08. Market Segmentation of Hemophilia Market by Type
08.1.1 Hemophilia A
08.1.2 Hemophilia B
08.1.4 Von WilleBrand Disease
08.2 Global Hemophilia A Market
08.2.1 Market Size and Forecast
08.3 Global Hemophilia B Market
08.3.1 Market Size and Forecast
08.4 Global Hemophilia Inhibitors Market
08.4.1 Market Size and Forecast
08.5 Global von Willebrand Disease Market
08.5.1 Market Size and Forecast
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2013
17.3 Prominent Vendors
18. Key Vendor Analysis
18.1 Baxter International Inc.
18.1.1 Business Overview
18.1.2 Business Segmentation
18.1.3 Key Information
18.1.4 SWOT Analysis
18.2 Novo Nordisk A/S.
18.2.1 Business Overview
18.2.2 Business Segmentation
18.2.3 Key Information
18.2.4 SWOT Analysis
18.3 Bayer AG
18.3.1 Business Overview
18.3.2 Business Segmentation
18.3.3 Key Information
18.3.4 SWOT Analysis
18.4 Pfizer Inc.
18.4.1 Business Overview
18.4.2 Business Segmentation
18.4.3 Key Information
18.4.4 SWOT Analysis
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Hemophilia Market 2013-2018 (US$ billion)
Exhibit 3: Global Hemophilia market-Segmentation by Types
Exhibit 4: Global Hemophilia Market By Type 2013
Exhibit 5: Global Hemophilia Market By Type 2013 (US$billion)
Exhibit 6: Global Hemophilia A Therapeutics Market 2013-2018 (US$billion)
Exhibit 7: Global Hemophilia B Therapeutics Market 2013-2018 (US$billion)
Exhibit 8: Global Hemophilia Inhibitors Market 2013-2018
Exhibit 9: Global von Willebrand Disease Market 2013-2018 (US$ billion)
Exhibit 10: Global Hemophilia Market by Geographical Segmentation 2013
Exhibit 11: Global Hemophilia Market by Vendor Segmentation 2013
Exhibit 12: Business Segmentation of Baxter International Inc.
Exhibit 13: Business Segmentation of Novo Nordisk A/S
Exhibit 14: Business Segmentation of Baxter International Inc.
Exhibit 15: Business Segmentation of Pfizer Inc.
Commenting on the report, an analyst from the team said: “Currently, most of the therapeutic hemophilia products are short acting, i.e., used only for when the patient suffers from bleeding. Further, many of these products exhibit immunogenic reactions resulting in a reduced effect of the therapeutic. In order to mitigate these issues, technologies such as PEGylation, recombinant DNA, and protein fusion technology, were developed and applied in the production of new therapies with a longer life span and fewer immunogenic reactions. For example, Biogen Idec is developing a next generation Hemophilia A therapy. The firm's leading therapeutic product, rFVIIIFc, is a recombinant - a truncated version of factor VIII, fused to the Fc domain of an antibody to extend half-life in the bloodstream. The resultant recombinant product is a result of Biogen's protein fusion technology. Thus, increase in technological innovations is expected to drive the Global Hemophilia market during the forecast period.”
According to the report, one of the major drivers in this market is the increase in the development of new hemophilia therapeutics. Currently, there are large number of products in the pipeline being developed by vendors which are aimed at addressing Hemophilia A, Hemophilia B, and von WilleBrand disease. The anticipated approval of these pipeline products is expected to contribute to the growth of the market during the forecast period.
Further, the report states that one of the major challenges in this market is the high cost of hemophilia therapeutics. The high cost is attributed to the longer time taken to manufacture hemophilia prophylactics and manufacturing constraints.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Bayer AG.
- Baxter International Inc.
- Biogen Idec
- CSL Behring LLC.
- Grifols S.A
- Inspiration Biopharmaceuticals Inc.
- Kedrion Biopharma Inc.
- Novo Nordisk A/s-b.
- Octapharma AG.
- Pfizer Inc.
- Swedish Orphan Biovitrum AB.